Evidence map›Paper›PMID 19154624›Full record

ArticleParasites & vectors2009

Onchocerciasis Control: Vision for the Future from a Ghanian perspective.

Mark J Taylor, Kwablah Awadzi, María-Gloria Basáñez, Nana Biritwum, Daniel Boakye, Boakye Boatin, Moses Bockarie, Thomas S Churcher, Alex Debrah, Geoffrey Edwards and 7 more

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03517462 nacompletednot on this mapstarted 2018, after this paper: background citation

Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis

TypeinterventionalSponsorWashington University School of MedicineRan2018 to 2019Enrolled231ConditionsOnchocerciasisArmsIvermectin 3Mg Tab
NCT04188301 phase2completednot on this mapstarted 2019, after this paper: background citation

Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis

TypeinterventionalSponsorWashington University School of MedicineRan2019 to 2022Enrolled154ConditionsOnchocerciasisArmsIVM w/ ALB, Single dose of IDA, Three daily doses of IDA
NCT06070116 phase2active not recruitingnot on this mapstarted 2024, after this paper: background citation

Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis

TypeinterventionalSponsorWashington University School of MedicineRan2024 to 2026Enrolled300ConditionsOnchocercal Subcutaneous Nodule, Onchocerciasis, Onchocerciasis, Ocular, Onchocerca InfectionArmsIvermectin w/ Albendazole, Ivermectin + Diethylcarbamazine + Albendazole, Moxidectin + Albendazole, Moxidectin + Diethylcarbamazine + Albendazole
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Heme acquisition in the parasitic filarial nematode Brugia malayi.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016
    Article
  14. Article
  15. Article
  16. Does Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Article
  17. Article
  18. Article
  19. Article
  20. Repurposing drugs for the treatment and control of helminth infections.International journal for parasitology. Drugs and drug resistance · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 5 countries.

Mark J TaylorMolecular and Biochemical Parasitology, Liverpool School of Tropical Medicine, Liverpool, UK. mark.taylor@liverpool.ac.uk.
Kwablah Awadzi
María-Gloria Basáñez
Nana Biritwum
Daniel Boakye
Boakye Boatin
Moses Bockarie
Thomas S Churcher
Alex Debrah
Geoffrey Edwards
Achim Hoerauf
Sabine Mand
Graham Matthews
Mike Osei-Atweneboana
Roger K Prichard
Samuel Wanji
Ohene Adjei
Imperial College London · GBLiverpool School of Tropical Medicine · GBKwame Nkrumah University of Science and Technology · GHMcGill University · CAUniversity of Bonn · DEGhana Health Service · GHNoguchi Memorial Institute for Medical Research · GHWorld Health Organization · CH

Funding

Medical Research Council G0200123
6 · The paper itself

Abstract

Since 1987 onchocerciasis control has relied on the donation of ivermectin (Mectizan(R), Merck & Co., Inc.) through the Mectizan Donation Programme. Recently, concern has been raised over the appearance of suboptimal responses to ivermectin in Ghana - highlighting the potential threat of the development of resistance to ivermectin. This report summarises a meeting held in Ghana to set the research agenda for future onchocerciasis control. The aim of this workshop was to define the research priorities for alternative drug and treatment regimes and control strategies to treat populations with existing evidence of suboptimal responsiveness and define research priorities for future control strategies in the event of the development of widespread ivermectin resistance.

Identifiers

PMID19154624
PMCPMC2639371
OpenAlexW2051856294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.